MA54471A - Composé agoniste de récepteur thrb, son procédé de préparation et son utilisation - Google Patents
Composé agoniste de récepteur thrb, son procédé de préparation et son utilisationInfo
- Publication number
- MA54471A MA54471A MA054471A MA54471A MA54471A MA 54471 A MA54471 A MA 54471A MA 054471 A MA054471 A MA 054471A MA 54471 A MA54471 A MA 54471A MA 54471 A MA54471 A MA 54471A
- Authority
- MA
- Morocco
- Prior art keywords
- thrb
- preparation
- receptor agonist
- agonist compound
- compound
- Prior art date
Links
- 101000712600 Homo sapiens Thyroid hormone receptor beta Proteins 0.000 title 1
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811527414.4A CN111320609A (zh) | 2018-12-13 | 2018-12-13 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54471A true MA54471A (fr) | 2021-10-20 |
Family
ID=71071432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054471A MA54471A (fr) | 2018-12-13 | 2019-12-12 | Composé agoniste de récepteur thrb, son procédé de préparation et son utilisation |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11084802B2 (fr) |
| EP (1) | EP3893889A4 (fr) |
| JP (1) | JP2022512482A (fr) |
| KR (1) | KR20210102328A (fr) |
| CN (3) | CN111320609A (fr) |
| AR (1) | AR117694A1 (fr) |
| AU (1) | AU2019398339A1 (fr) |
| BR (1) | BR112021010871A2 (fr) |
| CA (1) | CA3120880A1 (fr) |
| CL (1) | CL2021001521A1 (fr) |
| CO (1) | CO2021008817A2 (fr) |
| IL (2) | IL310699A (fr) |
| MA (1) | MA54471A (fr) |
| MX (1) | MX2021006908A (fr) |
| PE (1) | PE20211788A1 (fr) |
| SG (1) | SG11202106194TA (fr) |
| TW (1) | TWI837244B (fr) |
| WO (1) | WO2020123827A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014043706A1 (fr) | 2012-09-17 | 2014-03-20 | Madrigal Pharmaceuticals, Inc. | Procédé de synthèse d'analogues de l'hormone thyroïdienne et de ses polymorphes |
| AU2019287679B2 (en) | 2018-06-12 | 2022-04-21 | Xizang Haisco Pharmaceutical Co., Ltd. | Thyroid hormone receptor agonists and uses thereof |
| AU2019357618A1 (en) | 2018-10-12 | 2021-04-29 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2020227549A1 (fr) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATEURS DE THR-β ET LEURS PROCÉDÉS D'UTILISATION |
| CN111909137B (zh) * | 2019-05-10 | 2023-05-30 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
| CN114174282A (zh) * | 2019-05-29 | 2022-03-11 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
| TW202128668A (zh) * | 2019-12-16 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 并環類衍生物、其製備方法及其在醫藥上的應用 |
| CN115811972A (zh) * | 2020-05-13 | 2023-03-17 | 拓臻制药公司 | 肝脏病症的组合治疗 |
| IL300853A (en) | 2020-08-25 | 2023-04-01 | Lilly Co Eli | SSAO inhibitor polymorphs |
| WO2022053028A1 (fr) * | 2020-09-10 | 2022-03-17 | 南京明德新药研发有限公司 | Composé de 1,2,4-triazine-3,5-(2h,4h)-dicétone et son utilisation |
| EP4215524A1 (fr) * | 2020-09-17 | 2023-07-26 | Sunshine Lake Pharma Co., Ltd. | Composé servant d'agoniste du récepteur beta de l'hormone thyroïdienne et utilisations du composé |
| EP4232436A1 (fr) * | 2020-10-23 | 2023-08-30 | Madrigal Pharmaceuticals, Inc. | Procédé de préparation de dérivés de 6-(4-nitro-phénoxy)-2h-pyridazin-3-one et de 6-(4-amino-phénoxy)-2h-pyridazin-3-one en tant qu'intermédiaires d'analogues des hormones thyroïdiennes |
| CA3197249A1 (fr) * | 2020-11-06 | 2022-05-12 | David Craig Mcgowan | Pyridazinones bicycliques comme beta-agonistes du recepteur des hormones thyroidiennes |
| CN116925045A (zh) * | 2020-12-15 | 2023-10-24 | 中国科学院上海药物研究所 | 甲状腺素受体β选择性激动剂化合物、其药物组合物和用途 |
| CN114685450A (zh) | 2020-12-30 | 2022-07-01 | 昆药集团股份有限公司 | 2-吡啶酮类衍生物及其制备方法和在医药上的应用 |
| KR20230152095A (ko) * | 2021-03-03 | 2023-11-02 | 테른스 파마슈티칼스, 인크. | 갑상선 호르몬 수용체 베타 작용제 화합물 |
| US20230241071A1 (en) * | 2021-11-11 | 2023-08-03 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| WO2023083288A1 (fr) * | 2021-11-11 | 2023-05-19 | Terns Pharmaceuticals, Inc. | TRAITEMENT DE TROUBLES HÉPATIQUES AVEC UN AGONISTE DE THR-β |
| WO2023154842A1 (fr) * | 2022-02-10 | 2023-08-17 | Madrigal Pharmaceuticals, Inc. | Analogues du thr bêta et leurs utilisations |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0377903A3 (fr) * | 1989-01-09 | 1991-07-17 | Bayer Ag | Des hexahydro-1,2,4-triazinediones substitués, procédés pour leur préparation, des intermédiaires et leur utilisation |
| US6787652B1 (en) | 1999-09-30 | 2004-09-07 | Pfizer, Inc. | 6-Azauracil derivatives as thyroid receptor ligands |
| JP2004517851A (ja) | 2000-12-27 | 2004-06-17 | バイエル アクチェンゲゼルシャフト | 甲状腺受容体のリガンドとしてのインドール誘導体 |
| US7230031B2 (en) | 2002-01-30 | 2007-06-12 | Kissei Pharmaceutical Co., Ltd. | Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| AU2003225305A1 (en) | 2002-05-08 | 2003-11-11 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| FR2882750B1 (fr) | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| DK1919878T3 (da) * | 2005-07-21 | 2010-10-25 | Hoffmann La Roche | Pyridazinonderivater som thyroidhormonreceptoragonister |
| BRPI1015096A2 (pt) | 2009-04-20 | 2016-05-03 | Mitsubishi Tanabe Pharma Corp | agonista de receptor beta de hormônio tireoideano |
| WO2011038207A1 (fr) | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Agonistes des récepteurs des hormones thyroïdiennes contenant du phosphore et méthodes d'utilisation |
| CN103958497B (zh) | 2011-11-14 | 2017-09-01 | 亚尼塔公司 | 作为AXL和c‑MET激酶抑制剂的尿嘧啶衍生物 |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102898377B (zh) * | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | 一类酞嗪酮衍生物及其用途 |
| JP6814730B2 (ja) | 2014-09-05 | 2021-01-20 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
| IL266054B2 (en) * | 2016-10-18 | 2023-10-01 | Madrigal Pharmaceuticals Inc | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
| US11485729B2 (en) | 2018-01-23 | 2022-11-01 | Shenzhen Targetrx, Inc. | Substituted pyridazinone compound |
| AU2019287679B2 (en) * | 2018-06-12 | 2022-04-21 | Xizang Haisco Pharmaceutical Co., Ltd. | Thyroid hormone receptor agonists and uses thereof |
| WO2020041741A1 (fr) | 2018-08-24 | 2020-02-27 | Terns, Inc. | Composés agonistes des récepteurs bêta des hormones thyroïdiennes |
| WO2020039076A1 (fr) | 2018-08-24 | 2020-02-27 | Plastic Omnium Advanced Innovation And Research | Ensemble pour un réservoir de fluide comprenant une chicane et une ligne de transfert de fluide traversant la chicane |
| AU2019359141A1 (en) | 2018-10-12 | 2021-04-22 | InventisBio Co., Ltd. | Thyroid hormone receptor agonists |
| AU2019357618A1 (en) | 2018-10-12 | 2021-04-29 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CN111484481A (zh) | 2019-01-26 | 2020-08-04 | 察略盛医药科技(上海)有限公司 | 哒嗪酮类衍生物、其制备方法及其在医药上的用途 |
| US20220162161A1 (en) | 2019-02-21 | 2022-05-26 | Nanjing Ruijie Pharma Co., Ltd. | Novel compounds and their uses as thyroid hormone receptor agonists |
| CN114174282A (zh) | 2019-05-29 | 2022-03-11 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
-
2018
- 2018-12-13 CN CN201811527414.4A patent/CN111320609A/zh active Pending
-
2019
- 2019-12-12 US US16/712,301 patent/US11084802B2/en active Active
- 2019-12-12 SG SG11202106194TA patent/SG11202106194TA/en unknown
- 2019-12-12 JP JP2021533640A patent/JP2022512482A/ja active Pending
- 2019-12-12 WO PCT/US2019/066013 patent/WO2020123827A1/fr unknown
- 2019-12-12 BR BR112021010871-8A patent/BR112021010871A2/pt unknown
- 2019-12-12 CA CA3120880A patent/CA3120880A1/fr active Pending
- 2019-12-12 CN CN201980081797.3A patent/CN113194958B/zh active Active
- 2019-12-12 TW TW108145594A patent/TWI837244B/zh active
- 2019-12-12 PE PE2021000858A patent/PE20211788A1/es unknown
- 2019-12-12 KR KR1020217021249A patent/KR20210102328A/ko unknown
- 2019-12-12 CN CN202310453989.0A patent/CN116444498A/zh active Pending
- 2019-12-12 EP EP19896475.1A patent/EP3893889A4/fr active Pending
- 2019-12-12 AR ARP190103650A patent/AR117694A1/es unknown
- 2019-12-12 AU AU2019398339A patent/AU2019398339A1/en active Pending
- 2019-12-12 MA MA054471A patent/MA54471A/fr unknown
- 2019-12-12 IL IL310699A patent/IL310699A/en unknown
- 2019-12-12 MX MX2021006908A patent/MX2021006908A/es unknown
-
2020
- 2020-09-04 US US17/013,314 patent/US11034676B2/en active Active
-
2021
- 2021-05-23 IL IL283362A patent/IL283362B2/en unknown
- 2021-06-10 CL CL2021001521A patent/CL2021001521A1/es unknown
- 2021-07-02 CO CONC2021/0008817A patent/CO2021008817A2/es unknown
-
2023
- 2023-05-10 US US18/315,291 patent/US20230278988A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL283362B2 (en) | 2024-07-01 |
| BR112021010871A2 (pt) | 2021-08-31 |
| US20200190064A1 (en) | 2020-06-18 |
| AR117694A1 (es) | 2021-08-25 |
| MX2021006908A (es) | 2021-07-07 |
| CL2021001521A1 (es) | 2022-01-28 |
| IL283362B1 (en) | 2024-03-01 |
| US11084802B2 (en) | 2021-08-10 |
| US11034676B2 (en) | 2021-06-15 |
| TW202039470A (zh) | 2020-11-01 |
| US20230278988A1 (en) | 2023-09-07 |
| SG11202106194TA (en) | 2021-07-29 |
| TWI837244B (zh) | 2024-04-01 |
| IL283362A (en) | 2021-07-29 |
| CN116444498A (zh) | 2023-07-18 |
| EP3893889A1 (fr) | 2021-10-20 |
| PE20211788A1 (es) | 2021-09-09 |
| EP3893889A4 (fr) | 2022-08-03 |
| CN111320609A (zh) | 2020-06-23 |
| CN113194958B (zh) | 2023-05-23 |
| CN113194958A (zh) | 2021-07-30 |
| KR20210102328A (ko) | 2021-08-19 |
| IL310699A (en) | 2024-04-01 |
| JP2022512482A (ja) | 2022-02-04 |
| WO2020123827A1 (fr) | 2020-06-18 |
| AU2019398339A1 (en) | 2021-06-10 |
| CA3120880A1 (fr) | 2020-06-18 |
| CO2021008817A2 (es) | 2021-07-19 |
| US20200399249A1 (en) | 2020-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54471A (fr) | Composé agoniste de récepteur thrb, son procédé de préparation et son utilisation | |
| EA201791286A1 (ru) | Схема дозирования для селективного агониста рецептора s1p | |
| EA201791882A1 (ru) | Агонисты 5ht для лечения нарушений | |
| IL279037A (en) | A pharmaceutical combination containing a glucose kinase activator and a PPAR receptor activator, composition, compound preparation, method of preparation and their uses | |
| IL281570A (en) | Methods for the purification of multispecific heterodimeric antibodies | |
| EP3840755A4 (fr) | Composés agonistes des récepteurs bêta des hormones thyroïdiennes | |
| CL2017002017A1 (es) | Compuestos con actividad antagonista de los receptoresmuscarínicos y actividad agonista del receptor beta2 adrenérgico | |
| ZA202100924B (en) | Time resources for uplink channels | |
| MA54396A (fr) | Procédé de préparation de n-phénylpyrazole-1-carboxamides | |
| EP3395113A4 (fr) | Procédé de planification distribuée pour une architecture de réseau sans fil c-ran de réseau radio fronthaul | |
| EP3138847A4 (fr) | Composé de type métallocène, composition catalytique le contenant et procédé pour la préparation d'une polyoléfine l'utilisant | |
| PL3733665T3 (pl) | Związki zawierające ugrupowanie 2-okso-1,3,4-tiadiazynan-3-ylowe mające aktywność agonisty receptora EP4 | |
| DK3860998T3 (da) | Forbindelser og sammensætninger til behandlinger af tilstande, der er forbundet med APJ-receptoraktivitet | |
| EP3942863C0 (fr) | Ressource de communication v2x pour un événement de mobilité | |
| IL271391A (en) | Scheduling method, device and system for transferring resources | |
| EP3796832C0 (fr) | Biocapteur à récepteur d'éthylène | |
| MA46199A (fr) | Composé cyclique aromatique de pyrido à cinq éléments, son procédé de préparation et son utilisation | |
| HK1251831A1 (zh) | 作為選擇性5-ht(2c)受體激動劑的環丙基甲胺 | |
| EP3750879A4 (fr) | Agoniste du récepteur de la prostacycline | |
| GB2577527B (en) | Network slice management | |
| GB201903900D0 (en) | Adenosine receptor agonists | |
| GB2577525B (en) | Network slice management | |
| GB2577526B (en) | Network slice management | |
| NO20210023A1 (en) | Advanced stabilizing system for deep drilling | |
| GB201914756D0 (en) | Cyclic apelin receptor agonists |